ReviewRSC advances2026
Privileged nitrogen heterocycles in anticancer drug discovery: recent advances on imidazole, indole, and pyrimidine scaffolds.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imidazoles, indoles, and pyrimidines are promising heterocyclic scaffolds for anticancer drug discovery. Based on the literature from 2020 to 2025, this review summarises that structurally diverse imidazoles, particularly ether-linked and long-chain variants, exhibit robust anticancer activity through multi-target protein inhibition and minimal off-target effects. Indoles trigger apoptosis and inhibit angiogenesis, while pyrimidines and their hybrids exhibit nanomolar potency and often outperform conventional chemotherapy. These scaffolds collectively modulate important pathways in cancer and exhibit enhanced selectivity toward tumour cells; however, clinical translation is challenging mainly due to incomplete mechanism of action and pharmacokinetics. Further rational optimisation and green synthesis methods may accelerate the development of these heterocycles into next-generation anticancer agents.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.